• Muscimol, thought to be a agonist of γ-aminobutyric acid (GABA), was administered to eight neuroleptic-free subjects with tardive dyskinesia. At oral dose levels from 5 to 9 mg, involuntary movements were consistently attenuated, usually in the absence of sedation. These results support the view that pharmacologic attempts to stimulate GABA-mediated synaptic transmission may afford symptomatic relief to patients with tardive dyskinesia.
Tamminga CA, Crayton JW, Chase TN. Improvement in Tardive Dyskinesia After Muscimol Therapy. Arch Gen Psychiatry. 1979;36(5):595–598. doi:10.1001/archpsyc.1979.01780050105013